MedTrace Logo

A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants

NCT03888755 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-06-03

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the efficacy, pharmacokinetics (PK), and safety of icatibant for the treatment of acute attacks in Japanese participants with type I or type II hereditary angioedema (HAE).

Conditions

  • Hereditary Angioedema (HAE)

Interventions

DRUG

Icatibant

Participants will receive icatibant 30 mg SC injection in the abdominal area.

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-18
Primary Completion
2016-02-12
Completion
2016-02-12

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03888755 on ClinicalTrials.gov